In pancreatic tumor models, the HSP90 inhibitors, NVP-AUY922 and ganetespib, were shown to suppress angiogenesis and tumor growth [161,162], whereas geldanamycin exhibited anticancer and pro-apoptotic activity in gastric cancer and cholangiocarcinoma cells, as s single agent or in combination with NVP-AUY922. This evidence concerns the gene HSP90AA1 and cholangiocarcinoma.